This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Silva RS , Kido LA , Montico F , Vendramini-Costa DB , Pilli RA , Cagnon VHA
Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice
Cell Biol Int. 2018 Aug;42(8) :1006-1020
PMID: 29603508 URL: https://www.ncbi.nlm.nih.gov/pubmed/29603508
AbstractProstate cancer is the second most diagnosed cancer in the world, and alternative methods to prevent and treat different lesion grades need to be evaluated. The objective was to evaluate the morphological, hormonal and inflammatory responses in the prostate anterior lobe in transgenic adenocarcinoma of the mouse prostate (TRAMP), following Celecoxib and Goniothalamin (GTN) treatments. All animals were treated for 4 weeks, from 8 weeks of age and euthanized either immediately after treatment (12-week-old mice: immediate response) or later (22-week-old mice: late response). The results showed a significant increase of high-grade prostatic intraepithelial neoplasia (HGPIN) and well-differentiated adenocarcinoma (WDA), according to the age in the control groups. Celecoxib treatment decreased the WDA incidence in the late response group. GTN led to a significant healthy tissue increase, and an LGPIN and HGPIN decrease in the immediate response group. In the late response group, GTN led to healthy area increase and there was no occurrence of WDA. AR and ERalpha immunoexpressions were reduced by both treatments in the immediate response groups. However, only GTN was able to decrease the ERalpha level in the late response group. Regarding COX-2 immunoreactivity, both treatments reduced the frequency of this enzyme. We can conclude that the prostate anterior lobe is a good model to study prostate cancer, considering its slow progression. Both treatments led to cancer delay in the prostate anterior lobe. However, GTN pointed towards a better treatment spectrum in the signaling pathways in the prostate microenvironment, particularly in ERalpha.
Notes1095-8355 Silva, Rafael Sauce Kido, Larissa Akemi Montico, Fabio Vendramini-Costa, Debora Barbosa Pilli, Ronaldo Aloise Cagnon, Valeria Helena Alves Journal Article England Cell Biol Int. 2018 Mar 30. doi: 10.1002/cbin.10967.